In this issue, we describe the numerous benefits of incorporating a stable isotope labelled internal standard for quantitative liquid chromatography-mass spectrometry, and detail recent advances in MS technology. Several case studies are presented, which exemplify novel bioanalytical workflows that are required to meet the challenges faced in both non-clinical and clinical development, across a variety of drug classes.

- 0:42 Introduction
- 5:33 The Case for Stable Isotope Labelled Internal Standards for LCMS Quantitation
- 8:34 Recent Innovations in Mass Spectrometry
- 15:38 Case Study: Dried Blood Microsampling
- 17:14 Case Study: Anti-Epileptic Drug Panel
- 19:17 Case Study: COVID-19 Neutralizing Monoclonal Antibody
- 21:16 Case Study: Differential Mobility Spectrometry (DMS)
- 23:49 Case Study: Bioequivalence 
- 26:22 Case Study: Oligonucleotides
- 33:57 Conclusion

Click here to download a readable, PDF version of Issue 13: https://www.altasciences.com/sites/default/files/2022-12/The-Altascientist-issue-30-LCMS.pdf

About Altasciences:

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Issue 30 — The Evolution and Advancement of LCMS in Drug Development

According to the World Health Organization, at least a billion people are currently living with vision impairment from a preventable or treatable source. The main conditions causing their distance vision impairment or blindness are cataracts, refractive error, age-related macular degeneration, glaucoma, diabetic retinopathy, and presbyopia. 

Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion in 2021 to an estimated $68.93 billion by 2030. The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches. For conditions that require surgery or corrective devices, eye drops are an important part of diagnosis, and pre- and post-surgery treatment plans. 

In this issue of The Altascientist, we explore how to meet the challenges of formulation development for ocular therapies. 


Issue 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics

As an end-to-end CRO/CDMO, we have expert knowledge in all early stages of drug development, and we’re sharing that knowledge with you in The Altascientist: The Audiobook. 

Each issue is a deep dive into a specific area of early-phase drug development, providing insider tips, considerations, and case studies. 


Altasciences is a drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.

Issue 30 — The Evolution and Advancement of LCMS in Drug Development

The Altascientist

Related tracks